Exploring the iron metabolism in multidrug resistant tuberculosis (MDR-TB) patients in treatment

Bahi, Gnogbo Alexis; Bidie, A.P.; Souleymane, Méité; Djaman, Allico Joseph

doi:10.4314/ijbcs.v11i3.9

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Iron plays an essential role in any aspect of metabolic mechanism, including immune system modulation. Mycobacterial infection may induce inflammatory anemia by producing cytokines: interferon-γ, TNF-α, IL-1, and IL-10, leading to iron sequestration by macrophages and erythropoietin suppression [40]. Anemia also affects the culture conversion of MDR-TB patients, but the mechanism is not clear yet [41].…”

Section: Plos Onementioning

confidence: 99%

Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia

et al. 2022

View full text Add to dashboard Cite

Background and aims Multi drug or rifampicin resistant tuberculosis (MDR/RR-TB) is a major burden to TB prevention and eradication globally. Since 2016, WHO guidelines have included options for treating MDR/RR-TB with a standard regimen of 9 to 11 months duration (the ’shorter regimen’) rather than an individual regimen of at least 20 months. This regimen has been introduced in Indonesia since September 2017. Therefore, we aimed to determine the success rate and factors associated with the treatment outcome of shorter injectable based regimen in West Java province, Indonesia. Methods This was a retrospective cohort study of MDR/RR-TB patients aged over 18 years old who received the shorter injectable based regimen between September 2017 and December 2020. We defined successful outcomes as the combined proportion of patients who were cured or had complete treatment. While, unsuccessful outcomes were defined as the combined proportion of patients who died from any causes, failure, and loss to follow-up (LTFU). Results A total of 315 patients were included in this study. The success rate was 64.5%. Multivariate analysis showed male gender (aRR = 1.18, 95% CI 1.04 to 1.34) increased the chance of successful outcome, while malnutrition (aRR = 0.78, 95% CI 0.68 to 0.89), history of previous TB treatment (aRR = 0.80%CI 0.68 to 0.94), and time of culture conversion >2 months (aRR = 0.72 (95% CI 0.59 to 0.87) decreased the chance of successful outcome. Conclusion History of previous TB treatment, time of culture conversion >2 months, and malnutrition were independent factors that decrease the chance for success rate, while male gender increase the likelihood for success rate of patients treated by the shorter injectable based regimen.

show abstract

Section: Plos Onementioning

confidence: 99%

Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There is evidence that mycobacterial infection can lead to inflammatory anaemia by inducing production of cytokines such as IL-1, IL-10, interferons-γ and TNF-α which cause macrophages to sequester iron and suppress erythropoietin levels [13]. There are many metabolic processes that require iron as a key factor, including immune system modulation [14]. In India, anaemia is very common and more prevalent among lower socio-economic class patients [15].…”

Section: Discussionmentioning

confidence: 99%

Factors affecting the treatment outcome of injection based shorter MDR-TB regimen at a referral centre in India

Kiran

Singla

et al. 2022

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Rifampicin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) is a significant burden on global tuberculosis (TB) prevention and eradication efforts. MDR-TB can be treated, but it is expensive, takes a long time (typically two years), and contains potentially toxic drugs. Under certain conditions, the WHO recommends standard regimens lasting 9 to 11 months rather than individual regimens lasting at least 18-20 months. The current study sought to identify factors associated with treatment outcome in RR/MDR-TB patients receiving an injection-based regimen for 9-11 months. This ambispective (prospective and retrospective) observational study was conducted at a tertiary tuberculosis institute in New Delhi, India. Between February 2021 and March 2022, patients with RR/MDR-pulmonary TB who received an injection-based shorter regimen were enrolled. Factors related to treatment outcome were investigated and compared in patients who had a successful outcome versus those who did not. A total of 55 patients were enrolled, with 50.91% being successful (cured/treatment completed) and 49.09% failing (including failure, lost to follow up, death, and regimen changed). The following factors were significantly associated with the unsuccessful outcome, according to univariate analysis: BMI (18.5 kg/m2), anaemia, previous anti-TB treatment, bilateral chest X-ray involvement, and far advanced disease on chest X-ray BMI (18.5 kg/m2), anaemia, and far advanced disease on chest X-ray were all significantly associated with mortality. Anaemia was associated with an unsuccessful outcome (p=0.049) and mortality (p=0.048) in the multiple logistic regression analysis. Early treatment initiation, improved nutrition and anaemia, and regular monitoring can all improve RR/MDR-TB patients' outcomes and prognoses.

show abstract

Exploring the iron metabolism in multidrug resistant tuberculosis (MDR-TB) patients in treatment

Cited by 2 publications

References 8 publications

Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia

Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia

Factors affecting the treatment outcome of injection based shorter MDR-TB regimen at a referral centre in India

Contact Info

Product

Resources

About